FDA Approves First Treatment for MCT8 Deficiency
Unverified: this is what someone posted publicly. It hasn't been checked by this site, the brand, or any agency.
FDAU.S. Food and Drug Administration. It handles food, drink, cosmetic and medication recalls. Learn more → Approves First Treatment for MCT8 Deficiency
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
Flagged: rat, fda
View the original on Feed ↗ ← All reports